The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
Official Title: A Phase 1 Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
Study ID: NCT02483104
Brief Summary: This is a Phase 1, open-label, multicenter, dose escalation study evaluating the tolerability, safety, pharmacokinetics and preliminary efficacy of veliparib in combination with carboplatin and weekly paclitaxel in Japanese subjects with ovarian cancer.
Detailed Description:
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Site Reference ID/Investigator# 128815, Kurume-shi,Fukuoka, , Japan
Site Reference ID/Investigator# 128997, Morioka-shi, , Japan
Site Reference ID/Investigator# 128058, Nagaizumi-cho, , Japan
Name: Hideyuki Hashiba, BS
Affiliation: AbbVie GK.
Role: STUDY_DIRECTOR